CENTESSA PHARMACEUTICALS (260) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.148x

Based on the latest financial reports, CENTESSA PHARMACEUTICALS (260) has a cash flow conversion efficiency ratio of -0.148x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-72.22 Million ≈ $-84.44 Million USD) by net assets (€487.35 Million ≈ $569.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View today's stock price for CENTESSA PHARMACEUTICALS for real-time trading data and today's change.

CENTESSA PHARMACEUTICALS - Cash Flow Conversion Efficiency Trend (2022–2025)

This chart illustrates how CENTESSA PHARMACEUTICALS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see 260 market cap overview for the company's overall valuation and market capitalisation.

CENTESSA PHARMACEUTICALS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CENTESSA PHARMACEUTICALS ranked by their cash flow conversion efficiency. Also see CENTESSA PHARMACEUTICALS balance sheet assets for a full breakdown of the balance sheet.

Company	Cash Flow Conversion Efficiency
Science Applications International Corporation Common Stock NASDAQ:SAIC	0.089x
Samsung Securities KO:016360	-0.140x
Gerdau S.A F:GDUA	0.029x
Appfolio Inc NASDAQ:APPF	0.073x
Chewy Inc NYSE:CHWY	0.256x
Tsingtao Brewery Co Ltd SHG:600600	0.032x
Sona BLW Precision Forgings Limited NSE:SONACOMS	0.055x
Hubei Xingfa Chemicals Group Co Ltd SHG:600141	0.021x

Annual Cash Flow Conversion Efficiency for CENTESSA PHARMACEUTICALS (2022–2025)

The table below shows the annual cash flow conversion efficiency of CENTESSA PHARMACEUTICALS from 2022 to 2025. Review CENTESSA PHARMACEUTICALS free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€526.86 Million ≈ $615.96 Million	€-193.82 Million ≈ $-226.59 Million	-0.368x	-3.99%
2024-12-31	€401.55 Million ≈ $469.45 Million	€-142.06 Million ≈ $-166.08 Million	-0.354x	+47.88%
2023-12-31	€236.24 Million ≈ $276.19 Million	€-160.34 Million ≈ $-187.46 Million	-0.679x	-13.77%
2022-12-31	€336.17 Million ≈ $393.02 Million	€-200.55 Million ≈ $-234.46 Million	-0.597x	--

About CENTESSA PHARMACEUTICALS

F:260 Germany

Market Cap

$6.26 Billion

€5.35 Billion EUR

Market Cap Rank

#3468 Global

#643 in Germany

Share Price

€34.60

Change (1 day)

+0.00%

52-Week Range

€13.10 - €34.60

All Time High

€34.60